Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02490527 · ClinicalTrials.gov registry record · NA
Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02490527: Completed NA study, sponsored by University of California, San Diego.
NCT02490527 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02490527, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to gain insight into the side-effects of statin consumption, and assess the ability of epicatechin (a compound in dark chocolate) to counteract or reverse these changes. The investigators' prior research has shown that epicatechin can improve skeletal muscle structure and mitochondrial (which gives us energy) structure.
Primary Outcome
Cardiopulmonary exercise protocol will be used to measure VO2max to assess functional capacity.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Pure epicatechin capsules (50mg)
- DRUG Simvastatin (40mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-06 |
| Est. Completion | 2021-07-28 |
| Phase | NA |
What the finished NCT02490527 record still lists
NCT02490527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02490527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02490527 about?
NCT02490527 is a clinical study titled "Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity". The purpose of this study is to gain insight into the side-effects of statin consumption, and assess the ability of epicatechin (a compound in dark chocolate) to counteract or reverse these changes. The investigators' prior research has shown that epicatechin can improve skeletal muscle structure an...
What is the current status of trial NCT02490527?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2015-06. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT02490527?
The interventions under investigation include: Placebo (OTHER), Pure epicatechin capsules (50mg) (DIETARY_SUPPLEMENT), Simvastatin (40mg) (DRUG).
Who is sponsoring clinical trial NCT02490527?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02490527's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia